Incyte Corporation (INCY) is Sivik Global Healthcare LLC’s 7th Largest Position

Sivik Global Healthcare LLC lifted its stake in Incyte Corporation (NASDAQ:INCY) by 20.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 60,000 shares of the biopharmaceutical company’s stock after purchasing an additional 10,000 shares during the period. Incyte Corporation accounts for approximately 2.8% of Sivik Global Healthcare LLC’s holdings, making the stock its 7th largest holding. Sivik Global Healthcare LLC’s holdings in Incyte Corporation were worth $7,555,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Incyte Corporation by 22.7% in the 1st quarter. Vanguard Group Inc. now owns 15,415,857 shares of the biopharmaceutical company’s stock worth $2,060,638,000 after purchasing an additional 2,847,907 shares during the last quarter. State Street Corp boosted its position in shares of Incyte Corporation by 110.7% in the 1st quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock worth $1,013,437,000 after purchasing an additional 3,983,207 shares during the last quarter. FMR LLC boosted its position in shares of Incyte Corporation by 8.0% in the 1st quarter. FMR LLC now owns 2,980,864 shares of the biopharmaceutical company’s stock worth $398,452,000 after purchasing an additional 219,923 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Incyte Corporation by 42.0% in the 1st quarter. Geode Capital Management LLC now owns 1,780,064 shares of the biopharmaceutical company’s stock worth $237,618,000 after purchasing an additional 526,163 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Incyte Corporation by 23.9% in the 1st quarter. UBS Asset Management Americas Inc. now owns 1,477,461 shares of the biopharmaceutical company’s stock worth $197,492,000 after purchasing an additional 284,796 shares during the last quarter. Institutional investors and hedge funds own 91.06% of the company’s stock.

INCY has been the topic of several recent research reports. Zacks Investment Research upgraded Incyte Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. TheStreet upgraded Incyte Corporation from a “d+” rating to a “c” rating in a research report on Wednesday, May 24th. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $135.00 price target (up from $125.00) on shares of Incyte Corporation in a research report on Wednesday, May 31st. CIBC raised their price target on Incyte Corporation from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 31st. Finally, ValuEngine upgraded Incyte Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Eight analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Incyte Corporation has a consensus rating of “Buy” and an average target price of $142.16.

Incyte Corporation (INCY) traded down 0.51% during trading on Friday, reaching $119.15. The company had a trading volume of 2,995,901 shares. The company has a 50-day moving average price of $127.40 and a 200 day moving average price of $130.21. Incyte Corporation has a one year low of $81.49 and a one year high of $153.15. The company’s market capitalization is $24.51 billion.

Incyte Corporation (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.01). The firm had revenue of $326.40 million during the quarter, compared to analysts’ expectations of $318.45 million. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The company’s quarterly revenue was up 32.5% on a year-over-year basis. During the same quarter last year, the business posted $0.18 EPS. Analysts expect that Incyte Corporation will post ($0.84) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Incyte Corporation (INCY) is Sivik Global Healthcare LLC’s 7th Largest Position” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/17/incyte-corporation-incy-is-sivik-global-healthcare-llcs-7th-largest-position.html.

In other news, EVP Paula J. Swain sold 20,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $140.00, for a total transaction of $2,800,000.00. Following the completion of the transaction, the executive vice president now directly owns 55,067 shares of the company’s stock, valued at approximately $7,709,380. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 100,000 shares of Incyte Corporation stock in a transaction dated Friday, September 8th. The shares were bought at an average cost of $132.00 per share, with a total value of $13,200,000.00. The disclosure for this purchase can be found here. Insiders have sold a total of 54,252 shares of company stock valued at $7,206,984 over the last three months. Insiders own 17.70% of the company’s stock.

Incyte Corporation Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply